Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes

Cancer Cell

Volumn 20, Issue 1, 2011, Pages 92-103

  Scott, Kenneth L ^a   Nogueira, Cristina ^a,b   Heffernan, Timothy P ^a   van Doorn, Remco ^a,c   Dhakal, Sabin ^a   Hanna, Jason A ^d   Min, Chengyin ^a   Jaskelioff, Mariela ^a   Xiao, Yonghong ^a   Wu, Chang Jiun ^a   Cameron, Lisa A ^a   Perry, Samuel R ^a   Zeid, Rhamy ^a   Feinberg, Tamar ^a   Kim, Minjung ^a   Vande Woude, George ^e   Granter, Scott R ^f   Bosenberg, Marcus ^d   Chu, Gerald C ^a,f   DePinho, Ronald A ^a   Rimm, David L ^d   Chin, Lynda ^a,g   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b University of Porto   (Portugal)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE 5; ONCOPROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER MODEL; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CONSERVATION; GENETIC ENGINEERING; GENETIC SCREENING; GENOMICS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TRANSCRIPTOMICS; UPREGULATION;

EID: 79960034077     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.05.025     Document Type: Article

References (46)

1. Abe M., Hamada J., Takahashi O., Takahashi Y., Tada M., Miyamoto M., Morikawa T., Kondo S., Moriuchi T. Disordered expression of HOX genes in human non-small cell lung cancer. Oncol. Rep. 2006, 15:797-802.
2. Adams L.M., Warburton M.J., Hayman A.R. Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP). Cell Biol. Int. 2007, 31:191-195.
3. Berger A.J., Davis D.W., Tellez C., Prieto V.G., Gershenwald J.E., Johnson M.M., Rimm D.L., Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005, 65:11185-11192.
4. Bernards R., Weinberg R.A. A progression puzzle. Nature 2002, 418:823.
5. Camp R.L., Chung G.G., Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 2002, 8:1323-1327.
6. Capeller B., Caffier H., Sutterlin M.W., Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res. 2003, 23:1011-1015.
7. Chariot A., Castronovo V. Detection of HOXA1 expression in human breast cancer. Biochem. Biophys. Res. Commun. 1996, 222:292-297.
8. Chen L., Yang S., Jakoncic J., Zhang J.J., Huang X.Y. Migrastatin analogues target fascin to block tumour metastasis. Nature 2010, 464:1062-1066.
9. Chin K., de Solorzano C.O., Knowles D., Jones A., Chou W., Rodriguez E.G., Kuo W.L., Ljung B.M., Chew K., Myambo K., et al. In situ analyses of genome instability in breast cancer. Nat. Genet. 2004, 36:984-988.
10. Chin L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon-Cardo C., Horner J.W., DePinho R.A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997, 11:2822-2834.
11. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
12. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
13. Diaz-Rodriguez E., Sotillo R., Schvartzman J.M., Benezra R. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:16719-16724.
14. Ganss R., Montoliu L., Monaghan A.P., Schutz G. A cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J. 1994, 13:3083-3093.
15. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
16. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
17. Gould Rothberg B.E., Berger A.J., Molinaro A.M., Subtil A., Krauthammer M.O., Camp R.L., Bradley W.R., Ariyan S., Kluger H.M., Rimm D.L. Melanoma prognostic model using tissue microarrays and genetic algorithms. J. Clin. Oncol. 2009, 27:5772-5780.
18. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
19. Gurzov E.N., Izquierdo M. RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther. 2006, 13:1-7.
20. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001, 47:597-600.
21. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
22. Hashimoto Y., Skacel M., Adams J.C. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int. J. Biochem. Cell Biol. 2005, 37:1787-1804.
23. Honig A., Rieger L., Kapp M., Krockenberger M., Eck M., Dietl J., Kammerer U. Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study. BMC Cancer 2006, 6:199.
24. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.S., Sheahan M.D., Clark W.H., Tucker M.A., Dracopoli N.C. Germline p16 mutations in familial melanoma. Nat. Genet. 1994, 8:15-21.
25. Izumchenko E., Singh M.K., Plotnikova O.V., Tikhmyanova N., Little J.L., Serebriiskii I.G., Seo S., Kurokawa M., Egleston B.L., Klein-Szanto A., et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009, 69:7198-7206.
26. Kabbarah O., Nogueira C., Feng B., Nazarian R.M., Bosenberg M., Wu M., Scott K.L., Kwong L.N., Xiao Y., Cordon-Cardo C., et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 2010, 5:e10770.
27. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
28. Kim M., Gans J.D., Nogueira C., Wang A., Paik J.H., Feng B., Brennan C., Hahn W.C., Cordon-Cardo C., Wagner S.N., et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006, 125:1269-1281.
29. Lyubimova N.V., Pashkov M.V., Tyulyandin S.A., Gol'dberg V.E., Kushlinskii N.E. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull. Exp. Biol. Med. 2004, 138:77-79.
30. Maeda K., Hamada J., Takahashi Y., Tada M., Yamamoto Y., Sugihara T., Moriuchi T. Altered expressions of HOX genes in human cutaneous malignant melanoma. Int. J. Cancer 2005, 114:436-441.
31. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
32. O'Callaghan-Sunol C., Sherman M.Y. Heat shock transcription factor (HSF1) plays a critical role in cell migration via maintaining MAP kinase signaling. Cell Cycle 2006, 5:1431-1437.
33. O'Neill G.M., Seo S., Serebriiskii I.G., Lessin S.R., Golemis E.A. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007, 67:8975-8979.
34. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
35. Pawitan Y., Bjohle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7:R953-R964.
36. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
37. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33:49-54.
38. Rudolph K.L., Millard M., Bosenberg M.W., DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 2001, 28:155-159.
39. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
40. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98:262-272.
41. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
42. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
43. Vogt L., Schmitz N., Kurrer M.O., Bauer M., Hinton H.I., Behnke S., Gatto D., Sebbel P., Beerli R.R., Sonderegger I., et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J. Clin. Invest. 2006, 116:2817-2826.
44. Xu S., Sun Z., Li L., Liu J., He J., Song D., Shan G., Liu H., Wu X. Induction of T cells suppression by dendritic cells transfected with VSIG4 recombinant adenovirus. Immunol. Lett. 2010, 128:46-50.
45. Zhang X., Zhu T., Chen Y., Mertani H.C., Lee K.O., Lobie P.E. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J. Biol. Chem. 2003, 278:7580-7590.
46. Zheng Y., Lu Z. Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle 2009, 8:3474-3479.